Latest News
AnaptysBio, Inc.
- AnaptysBio Shares Fall 7.74% During GSK-Tesaro Post-Trial Hearing
- AnaptysBio (ANAB) On Jemperli Approval Is The Royalty Story Still A Bargain
- AnaptysBio Shares Rise After FDA Expands Jemperli Approval
- AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug
- FDA approves Jemperli for rectal cancer, benefiting AnaptysBio
- AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo
- AnaptysBio gains as GSK granted FDA label expansion for Jemperli
- AnaptysBio: Fully Valued; With Major Litigation Uncertainty (NASDAQ:ANAB)
- Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
- Anaptysbio director Renton Hollings sells $249,371 of shares
- AnaptysBio earnings beat by $5.58, revenue topped estimates
- How Return To Profit Will Impact AnaptysBio (ANAB) Investors
Headlines from the last 30 days, linking to the original publishers. See all market news →